Figure 11.Selection of appropriate drugs for glioma patients in the high-risk group. (A–E) OncoPredict showed that the drug scores for rapamycin, dasatinib, 5-fluorouracil and gemcitabine differed between glioma patients in the high- and low-risk groups. ***P < 0.001.
